IL229260A0 - Compositions,methods & systems for respiratory delivery of two or more active agents - Google Patents

Compositions,methods & systems for respiratory delivery of two or more active agents

Info

Publication number
IL229260A0
IL229260A0 IL229260A IL22926013A IL229260A0 IL 229260 A0 IL229260 A0 IL 229260A0 IL 229260 A IL229260 A IL 229260A IL 22926013 A IL22926013 A IL 22926013A IL 229260 A0 IL229260 A0 IL 229260A0
Authority
IL
Israel
Prior art keywords
compositions
systems
methods
active agents
respiratory delivery
Prior art date
Application number
IL229260A
Other languages
Hebrew (he)
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of IL229260A0 publication Critical patent/IL229260A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/02—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL229260A 2011-05-17 2013-11-05 Compositions,methods & systems for respiratory delivery of two or more active agents IL229260A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/036868 WO2012158166A1 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (1)

Publication Number Publication Date
IL229260A0 true IL229260A0 (en) 2014-01-30

Family

ID=47177229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229260A IL229260A0 (en) 2011-05-17 2013-11-05 Compositions,methods & systems for respiratory delivery of two or more active agents

Country Status (13)

Country Link
EP (1) EP2709447A4 (en)
JP (1) JP2014518871A (en)
KR (1) KR20140032404A (en)
CN (1) CN103687483A (en)
AU (1) AU2011368334A1 (en)
BR (1) BR112013029507A2 (en)
CA (1) CA2835927A1 (en)
EA (1) EA201490991A1 (en)
IL (1) IL229260A0 (en)
MX (1) MX2013013440A (en)
RU (1) RU2013155903A (en)
SG (1) SG194896A1 (en)
WO (1) WO2012158166A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763941A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG11201505556VA (en) 2013-01-31 2015-08-28 Prosonix Ltd Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
BR112015022784B1 (en) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc MICRONIZED CRYSTALLINE MATERIAL CONDITIONING METHOD AND CONDITIONING SYSTEMS
BR112015028964A2 (en) * 2013-05-22 2017-07-25 Pearl Therapeutics Inc suspension composition, and method for treating a pulmonary disease or disorder
BR112016014583B1 (en) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A COMPOSITION OF PHARMACEUTICAL SOLUTION IN AEROSOL, PRESSURIZED CALIBRATED DOSE INHALER AND USE OF SAID COMPOSITION
SG11201605309UA (en) * 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
MY181647A (en) 2014-09-09 2020-12-30 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
EP3288541B1 (en) * 2015-05-01 2020-09-02 Board of Regents, The University of Texas System Multidrug brittle matrix compositions
CN105125542A (en) * 2015-08-23 2015-12-09 杭州紫金医药科技有限公司 Medicine composition with tiotropium bromide and formoterol, application of medicine composition and preparation
CN106880637B (en) * 2015-12-15 2021-01-29 天津金耀集团有限公司 Ciclesonide formoterol and tiotropium bromide compound dry powder inhalant composition
CN106880636A (en) * 2015-12-15 2017-06-23 天津金耀集团有限公司 A kind of ciclesonide folk prescription and compound dry powder inhalation composition
CN106943350A (en) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 Aerosol and preparation method containing muscarinic receptor antagonist and β 2 receptor agonist
EP3880169A1 (en) * 2018-11-12 2021-09-22 Kindeva Drug Delivery L.P. Umeclidinium and vilanterol formulation and inhaler
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN111467498A (en) * 2020-05-14 2020-07-31 王兆霖 Pharmaceutical composition preparation
WO2022148418A1 (en) * 2021-01-08 2022-07-14 江苏恒瑞医药股份有限公司 Pharmaceutical composition capable of being delivered by metered dose inhaler
US20230026203A1 (en) * 2021-07-09 2023-01-26 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU750567B2 (en) * 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SI1718336T1 (en) * 2004-02-06 2008-10-31 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
CA2763941A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents

Also Published As

Publication number Publication date
CN103687483A (en) 2014-03-26
EA201490991A1 (en) 2014-09-30
CA2835927A1 (en) 2012-11-22
WO2012158166A1 (en) 2012-11-22
EP2709447A1 (en) 2014-03-26
KR20140032404A (en) 2014-03-14
JP2014518871A (en) 2014-08-07
MX2013013440A (en) 2014-06-05
EP2709447A4 (en) 2014-10-22
BR112013029507A2 (en) 2019-09-24
RU2013155903A (en) 2015-06-27
SG194896A1 (en) 2013-12-30
AU2011368334A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
IL229260A0 (en) Compositions,methods & systems for respiratory delivery of two or more active agents
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
ZA201903184B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1221654A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
EP2787071A4 (en) Equol concentration increasing agent containing psicose as active ingredient
HK1208188A1 (en) Formulations for the delivery of active ingredients
HK1179534A1 (en) Coated preparation containing azosemide as active ingredient
EP2692348A4 (en) Antitumor agent containing carbon dioxide as active ingredient
LT2704698T (en) Dosage form for the controlled release of active ingredients
HK1203068A1 (en) Systems and methods for generating germicidal compositions